BIOVIIIx is a biotech & pharmaceutical company operating in the field of bleeding disorders and rare disease, in particular the haemophilia segment. BIOVIIIx is a company born from the passion and conviction of a family project and today is, in fact, the only company in the pharma sector to be family-run. Thanks to the expertise of the team, and the emergence of numerous collaborations with various international partners, BIOVIIIx experiences a remarkable growth in a short period of time applying a model that provides great importance to scientific research always keeping in mind the relevance of respect given to people. BIOVIIIx aims at the optimization of treatments already available working on the development of increasingly advanced solutions for haemophilia and rare disorders in order to improve patient support. The company has always had a keen interest in investing in the training of its employees also focusing on business growth and modernization. This is the reason why BIOVIIIx invests part of its profit in annual scientific training for each employee and for team-building activities. Just as a percentage of the profit is used for digitization systems and for the implementation of R&D. The next steps for the consolidation of BIOVIIIx are aimed at its internationalization with new projects and collaborations at the international level. It is moving toward the creation of new Business Units, new investments, the study of new molecules aiming at new and broader horizons.